Education
About Us
Working with TipRanks
Follow Us
Cidara Therapeutics (CDTX)
NASDAQ:CDTX
CDTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$10.14 - $106.63
Previous CloseN/A
Volume155.01K
Average Volume (3M)915.51K
Market Cap
$2.45B
Enterprise Value$242.73M
Total Cash (Recent Filing)$510.57M
Total Debt (Recent Filing)$2.33M
Price to Earnings (P/E)―
Beta2.60
Next Earnings
Nov 06, 2025EPS Estimate
-1.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.65
Shares Outstanding25,358,051
10 Day Avg. Volume1,538,704
30 Day Avg. Volume915,506
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.10
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.67
Enterprise Value/Ebitda-1.96
Forecast
1Y Price Target
$135.00Price Target Upside32.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Market ExpansionThe market opportunity for CD388 continues to strengthen, with the expanded patient population bringing the addressable target population from ~50 million to over ~100 million in the U.S. alone.
Regulatory ApprovalsThe FDA has guided that if successful, a single trial of CD388 will be sufficient for a BLA submission.
Strategic PartnershipsCidara Therapeutics announced that it received an award valued up to $339M from the Biomedical Advanced Research and Development Authority (BARDA), which validates both the clinical utility and strategic importance of CD388.
Bears Say
Clinical TrialsThe ANCHOR Phase 3 study in influenza prevention has commenced, targeting enrollment of 6,000 subjects, which positions Cidara for commercial success pending trial readouts and regulatory reviews.
CompetitionCD388 provides a differentiated and novel approach to universally target influenza.
Cidara Therapeutics News
CDTX FAQ
What was Cidara Therapeutics’s price range in the past 12 months?
Cidara Therapeutics lowest stock price was $10.14 and its highest was $106.63 in the past 12 months.
What is Cidara Therapeutics’s market cap?
Cidara Therapeutics’s market cap is $2.45B.
When is Cidara Therapeutics’s upcoming earnings report date?
Cidara Therapeutics’s upcoming earnings report date is Nov 06, 2025 which is in 28 days.
How were Cidara Therapeutics’s earnings last quarter?
Cidara Therapeutics released its earnings results on Aug 07, 2025. The company reported -$1.65 earnings per share for the quarter, beating the consensus estimate of -$1.94 by $0.29.
Is Cidara Therapeutics overvalued?
According to Wall Street analysts Cidara Therapeutics’s price is currently Undervalued.
Does Cidara Therapeutics pay dividends?
Cidara Therapeutics does not currently pay dividends.
What is Cidara Therapeutics’s EPS estimate?
Cidara Therapeutics’s EPS estimate is -1.39.
How many shares outstanding does Cidara Therapeutics have?
Cidara Therapeutics has 25,358,051 shares outstanding.
What happened to Cidara Therapeutics’s price movement after its last earnings report?
Cidara Therapeutics reported an EPS of -$1.65 in its last earnings report, beating expectations of -$1.94. Following the earnings report the stock price went up 0.437%.
Which hedge fund is a major shareholder of Cidara Therapeutics?
Currently, no hedge funds are holding shares in CDTX
Cidara Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$135.00 (32.13% Upside)
$135.00 (32.13% Upside)
Blogger Sentiment
Bullish
CDTX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 3.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 13.1%
Last 30 Days ▲ 29.9%
Last 30 Days ▲ 29.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
784.86%
12-Months-Change
Fundamentals
Return on Equity
-37.05%
Trailing 12-Months
Asset Growth
208.22%
Trailing 12-Months
Company Description
Cidara Therapeutics
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.
CDTX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong positive outlook for Cidara Therapeutics due to successful clinical trial results, significant financial backing, and advancing regulatory discussions. However, challenges remain due to the company's non-revenue generating status and potential delays in Phase III study commencement.View all CDTX earnings summariesCDTX Stock 12 Month Forecast
Average Price Target
$135.00
▲(32.13% Upside)
Technical Analysis
Catalyst Pharma
―
IDEAYA Biosciences
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Tarsus Pharmaceuticals
―
Ownership Overview
17.91% Insiders
2.54% Mutual Funds
34.63% Other Institutional Investors
38.91% Public Companies and
Individual Investors